Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Abuse Deterrence Stories

2013-07-12 12:25:51

WASHINGTON, July 12, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) praised Signature Therapeutics, Inc. today for taking a national lead in biopharmaceutical research and development to reduce prescription drug abuse. Signature Therapeutics is a privately held company developing next-generation abuse-deterrent prescription medications. More than 2.7 percent of the U.S. population currently abuses prescription drugs.[1] In 2010,...

2013-06-11 12:28:37

WASHINGTON, June 11, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) joined in signing a Citizen Petition filed today urging the Food and Drug Administration (FDA) to fully implement the Obama administration's policy supporting a market transition to safer opioid medications. The petition asks that the FDA reject applications for new opioid medications without added safety features. Opioids are a class of synthetically derived chemicals often used to...

2013-01-09 20:20:49

WASHINGTON, Jan. 9, 2013 /PRNewswire-USNewswire/ -- Michael Barnes, Executive Director of the Center for Lawful Access and Abuse Deterrence (CLAAD) today released the following statements in response to the Obama-Biden Administration's issuance of draft guidance on the evaluation and labeling of abuse-deterrent opioid medications: The Obama-Biden Administration states that it intends to incentivize the development of safer medications, but its actions discredit its words. The...

2012-11-27 08:28:39

WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) today announced that it has selected Pisgah Laboratories' abuse-deterrent technology platform as one of its Top 5 Technologies To Reduce Prescription Drug Abuse. Pisgah Laboratories' lead abuse-deterrent technology product candidate Hydrocodone/APAP, is intended to provide relief to patients in need of treatment, yet lessen the potential for drug abuse. According to...

2012-11-27 08:28:38

WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) today recognized Egalet Ltd., a specialty pharmaceutical company focused on developing safe, effective, and tamper-resistant medications, as a Top Five Technologies To Reduce Prescription Drug Abuse honoree. Egalet is developing a pipeline of tamper-resistant opioids that are nearing pivotal testing. Roland Gerritsen van der Hoop, Chief Medical Officer of Egalet,...

2012-11-27 08:28:36

WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- At today's National Prescription Drug Abuse Prevention Policy Consensus Meeting, the not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) announced the results of its national contest to identify the "Top 5 Technologies To Reduce Prescription Drug Abuse." In alphabetical order, the Top 5 honorees are ... Atlantic Pharmaceuticals' SMART/Script dosage form to decrease medication tampering; Eagle Advancement...

2012-11-27 08:28:35

WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) today honored The Locking Cap as one of its "Top 5 Technologies To Reduce Prescription Drug Abuse." This small safe is the only 4-digit combination locking cap for prescription bottles on the market to prevent prescription drug abuse among unauthorized users. The Locking Cap's inventor Joseph Simpson began his crusade to stop prescription drug abuse in high school after witnessing...

2012-11-27 08:28:33

WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) today announced that Eagle Advancement Institute has been named a "Top 5 Technologies To Reduce Prescription Drug Abuse" honoree for its Clarity Rapid Detox program focused on opioid addiction. Clarity is a personalized, patented process that combines rapid detox and comprehensive aftercare delivered in person and via telehealth technology, including a customized...

2012-11-27 08:28:29

WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) today honored Atlantic Pharmaceuticals' SMART/Script as one of its "Top 5 Technologies To Reduce Prescription Drug Abuse." Still in investigational stages, the SMART/Script technology is intended to deliver immediate- and extended-release opioid medications in a tamper-resistant form. If a medication formulated with SMART/Script were crushed or chewed, the SMART/Script technology...

2012-11-16 20:21:27

Delaware Prescription Drug Abuse Summit Marks a Turning Point in National Epidemic, CLAAD Says. NEWARK, Del., Nov. 16, 2012 /PRNewswire-USNewswire/ --Today, a not-for-profit organization presenting at the Delaware Prescription Drug Abuse Summit appealed to the event's host, Attorney General Beau Biden, for assistance in preventing medication overdoses. The Center for Lawful Access and Abuse Deterrence (CLAAD) asked Biden to work closely with his father, Vice President Joe Biden, to...